Antonia Busse

1.5k total citations
54 papers, 1.1k citations indexed

About

Antonia Busse is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Antonia Busse has authored 54 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 26 papers in Immunology and 21 papers in Molecular Biology. Recurrent topics in Antonia Busse's work include Immunotherapy and Immune Responses (19 papers), CAR-T cell therapy research (16 papers) and Renal and related cancers (11 papers). Antonia Busse is often cited by papers focused on Immunotherapy and Immune Responses (19 papers), CAR-T cell therapy research (16 papers) and Renal and related cancers (11 papers). Antonia Busse collaborates with scholars based in Germany, United States and United Kingdom. Antonia Busse's co-authors include Ulrich Keilholz, Eckhard Thiel, Carmen Scheibenbogen, Anne Letsch, Alberto Fusi, Sebastian Ochsenreither, Igor Wolfgang Blau, Anne Marie Asemissen, A. Rietz and Lutz Uharek and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Antonia Busse

48 papers receiving 1.1k citations

Peers

Countries citing papers authored by Antonia Busse

Since Specialization

Citations

This map shows the geographic impact of Antonia Busse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonia Busse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonia Busse more than expected).

Fields of papers citing papers by Antonia Busse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonia Busse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonia Busse. The network helps show where Antonia Busse may publish in the future.

Co-authorship network of co-authors of Antonia Busse

This figure shows the co-authorship network connecting the top 25 collaborators of Antonia Busse. A scholar is included among the top collaborators of Antonia Busse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonia Busse. Antonia Busse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies 2025 ·Blood ·(unknown), (unknown), (unknown), (unknown), (unknown), Matthias Leisegang, (unknown), (unknown), Cäcilia Freund, Gerald Willimsky, Frank Konietschke, Elisa Kieback, Sarah K. Tasian, Bjoern Chapuy, Ulrich Keller, Thomas Blankenstein, Antonio Pezzutto, Antonia Busse	0
2	1600O Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial 2025 ·Annals of Oncology ·Sapna P. Patel, Apostolia M. Tsimberidou, Jason J. Luke, Winfried Alsdorf, Antonia Busse, (unknown), (unknown), Norbert Hilf, M. Alper Kursunel, Andrea Mayer-Mokler, Dmitry Pankov, Cedrik M. Britten, Martin Wermke, Leonel F. Hernandez‐Aya	0
3	611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors 2024 ·Annals of Oncology ·(unknown), Andréas Mackensen, (unknown), Winfried Alsdorf, (unknown), Daniel Heudobler, (unknown), Antonia Busse, Stephan Mielke, Sander Bins, Guy Ungerechts, Carsten Bokemeyer, Sebastian Klobuch, Nadine Kutsch, Fabian Müller, (unknown), Zhong Wei, (unknown), (unknown), Uğur Şahin	7
4	Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires 2022 ·Cancers ·(unknown), Gerald Willimsky, (unknown), (unknown), Leo Hansmann, Thomas Blankenstein, Eric Blanc, Dieter Beule, Ulrich Keller, Antonio Pezzutto, Antonia Busse	2
5	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial 2021 ·European Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), Enio Gjerga, Steffen Hennig, Sigrid Schaper, Il‐Kang Na, Ulrich Keller, Sara Y. Brucker, Thomas Decker, Peter A. Fasching, Tanja Fehm, Wolfgang Janni, Sherko Kümmel, Andreas Schneeweiß, Martin Schüler, Diana Lüftner, Antonia Busse	19
6	High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies 2021 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), Peter M. Kloetzel, (unknown), (unknown), Ulrich Keller, Antonio Pezzutto, Antonia Busse	11
7	Cancer testis antigen Cyclin A1 harbors several HLA-A02:01-restricted T cell epitopes, which are presented and recognized in vivo 2020 ·Cancer Immunology Immunotherapy* ·(unknown), (unknown), Petra Quass, Annika Nelde, Heiko Schuster, Anne Letsch, Antonia Busse, Juliane S. Walz, Ulrich Keilholz, Sebastian Ochsenreither	5
8	SigsPack, a package for cancer mutational signatures 2019 ·BMC Bioinformatics ·(unknown), Eric Blanc, (unknown), Thomas Blankenstein, Antonia Busse, Dieter Beule	13
9	Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients 2016 ·Cancer Immunology Immunotherapy ·(unknown), Anne Letsch, Anika Nonnenmacher, Kurt Miller, Ulrich Keilholz, Antonia Busse	13
10	Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study) 2013 ·Cancer Immunology Immunotherapy ·Antonia Busse, Jérôme Rapion, Alberto Fusi, Stefan Suciu, Anika Nonnenmacher, Mario Santinami, Wim H.J. Kruit, Alessandro Testori, Cornelis J.A. Punt, Angus Dalgleish, Alan Spatz, Alexander Eggermont, Ulrich Keilholz	5
11	Prognostic Relevance of Circulating Tumor Cells in Metastatic Uveal Melanoma 2011 ·Oncology ·R. Schuster, Nikolaos E. Bechrakis, Andrea Stroux, Antonia Busse, Alexander Schmittel, E. Thiel, M. H. Foerster, Ulrich Keilholz	24
12	Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma 2011 ·European Journal of Cancer ·Antonia Busse, Anne Marie Asemissen, Anika Nonnenmacher, (unknown), Sebastian Ochsenreither, David R. Stather, Alberto Fusi, Alexander Schmittel, Kurt Miller, Eckhard Thiel, Ulrich Keilholz	53
13	In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines 2010 ·Investigational New Drugs ·Martin Schmidt‐Hieber, (unknown), Andreas Weimann, Babette Aicher, Philipp Lohneis, Antonia Busse, Eckhard Thiel, Igor Wolfgang Blau	9
14	Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients 2010 ·Journal of Translational Medicine ·Sebastian Ochsenreither, Alberto Fusi, (unknown), Antonia Busse, Natascha C. Nüssler, Eckhard Thiel, Ulrich Keilholz, Dirk Nagorsen	12
15	Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination 2010 ·Journal of Translational Medicine ·Antonia Busse, Anne Letsch, Carmen Scheibenbogen, Anika Nonnenmacher, Sebastian Ochsenreither, Eckhard Thiel, Ulrich Keilholz	11
16	Immune Self-tuning in Renal Cell Carcinoma 2010 ·European Oncology & Haematology ·Antonia Busse, Ulrich Keilholz	2
17	Expression of the stem cell marker nestin in peripheral blood of patients with melanoma 2010 ·British Journal of Dermatology ·Alberto Fusi, Sebastian Ochsenreither, Antonia Busse, A. Rietz, Ulrich Keilholz	26
18	An intron 9 containing splice variant of PAX2 2009 ·Journal of Translational Medicine ·Antonia Busse, A. Rietz, Stefan Schwartz, Eckhard Thiel, Ulrich Keilholz	13
19	A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma 2007 ·Leukemia & lymphoma ·Antonia Busse, Gero Hütter, Jan Siehl, Alexander Schmittel, Eckhard Thiel, Ulrich Keilholz	0
20	Dose Response Study of Atopy Patch Test in Children with Atopic Eczema 1999 ·Pediatric Asthma Allergy & Immunology ·Ulf Darsow, Dieter Vieluf, (unknown), J. Berger, Antonia Busse, Wolfgang Czech, Angelika Heese, (unknown), Klaus‐Peter Peters, Bernhard Przybilla, G Richter, Franziska Ruëff, Thomas Werfel, (unknown), Johannes Ring	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact